Dr. Javid Moslehi is the Director of the Cardio-Oncology Program and an Associate Professor of Medicine at Vanderbilt. Dr. Moslehi is a cardiologist who has established preventive and treatment strategies for attenuating cardiovascular disease in cancer patients and cancer survivors. He is also a physician-scientist whose laboratory is interested in elucidating the mechanisms of cardiovascular and cardiometabolic complications associated with targeted cancer therapies, using cell-based and animal-based models to dissect the mechanism of toxicities from novel cancer therapies. His clinical and research group has ongoing collaborations with cardiologists and oncologists locally, nationally and internationally, as well as industry and regulatory bodies (including the US FDA). Dr. Moslehi is the chair of the American Heart Association (AHA) cardio-oncology subcommittee. In addition, he has established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology.
Eiman Jahangir MD, MPH, FACC, FAHA is a cardiologist and an Assistant Professor of Medicine at Vanderbilt. He joined as a clinician in the Cardio-Oncology section in January 2019. Dr. Jahangir is a native of Nashville, TN and obtained a Bachelors of Arts in Religious Studies at the George Washington University, Washington, DC as a University Honors Program Scholar. He received his medical degree at the University of Tennessee, Memphis, TN. Dr. Jahangir completed Internal Medicine Residency at Boston University Medical Center, Boston, MA. He completed his Fellowship in Cardiovascular Medicine at Vanderbilt University, Nashville, TN. He then completed advanced training in epidemiologic research while obtaining a Master’s of Public Health at Vanderbilt University. Dr. Jahangir served as a National Institute of Health (NIH) Fogarty International Clinical Research Fellow (FICR-F) in Buenos Aires, Argentina studying the prevalence of hypertension in the Southern Cone (Argentina, Chile, and Uruguay).
Dr. Jahangir’s clinical interests are in prevention of cardiovascular disease with a focus on cardiac-oncology. Dr. Jahangir is board certified in Internal Medicine and Cardiovascular Disease. Dr. Jahangir was founder and co-director of the Cardio-Oncology Clinic at Ochsner Medical Center in 2013. He currently is an Assistant Professor at Vanderbilt University Medical Center and spearheading the inpatient cardio-oncology service. He has published over 30 manuscripts in peer-reviewed journals, many on the topic of cardio-oncology and has served on the American College of Cardiology’s Round Table in cardio-oncology.
Dr. Slosky is a cardiologist and a Assistant Professor of Medicine at Vanderbilt. He has a special interest in the care of patients with cancer and complications of cancer therapy, risk of heart disease, and pre-existing cardiovascular disease. He has an active clinical practice that bridges the two specialties and provides focused care for these patients during their therapy and into survivorship. He has developed a multi-disciplinary group of collaborators that bring expertise and precision care for cancer patients. An example of this effort involves clinical and basic research in the field of thrombosis (blood clots) in patients with cancer. This is a major problem for these individuals and this effort is a unique example of translational research from the bedside to the bench. Dr. Slosky is board certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology.
Dr. Joe-Elie Salem is an adjunct professor of medicine and clinical pharmacology at Vanderbilt. Dr. Salem is a trained cardiologist and pharmacologist, is an Associate Professor of Medicine at Sorbonne, and is the director of the cardio-oncology program at Pitie-Salpetriere. Dr. Joe-Elie Salem’s research interests include cardiovascular pharmacology, cardio-immunology, heart failure and drug-induced arrhythmias applied to cardio-oncology. He obtained his medical degree, medical residency and cardiovascular medicine training at Rene Descartes (Paris V) and Pierre and Marie Curie University (Paris VI) at University of Paris (Sorbonne), with additional diplomas in cardiovascular imaging (echocardiography, CT and MRI. During this time, he also completed a PhD thesis at Sorbonne University in clinical pharmacology focused on the efficacy, sources of variability, and occurrence of adverse effects of cardiovascular drugs. His PhD research focus was on the development of new tools to predict deleterious drug effects on cardiac repolarization (i.e., drug-induced long QT syndrome). From 2013 to 2017, He was Assistant Professor of Pharmacology at the Clinical Investigation Center (CIC) at Hopitaux de Paris and Pierre and Marie Curie University (Sorbonne). His experience led me to conceive, participate and assist in the coordination of numerous translational research programs and clinical trials, mainly in the field of cardio-metabolism and pharmacology. From 2017 to 2018, he was a clinical cardio-oncology fellow and a post-doc fellow in clinical pharmacology at Vanderbilt. During this year at Vanderbilt, his first research focus was on cardio-oncology, particularly cardio-immunology and influence of hormone therapy on arrhythmia risk. His other focus was on precision medicine, notably using DNA linked electronic health record cohorts seeking for genetic variants associated with cardiac arrhythmias. Since 2018, he has been associate professor at Sorbonne Université and executive assistant director of a cardio-metabolism clinical investigation center at Paris Est. His current focus is to create a cardio-oncology program at Sorbonne Université and foster research in this field, in collaboration with Vanderbilt, where he has an adjunct associate professor position. His scientific contributions include:
Dr. Force is a Professor of medicine and Director of Cardiovascular Research at Vanderbilt. Since 1986, he has focused his research on molecular mechanisms of injury to the heart, especially as a result of perturbations in protein kinase signaling. The emergence of novel tyrosine kinase inhibitors used in cancer therapy and their potential cardiac complications brought a translational aspect to his research program. Since 2005, he has tried to identify molecular mechanisms of toxicity. Dr. Force graduated from Harvard College and Harvard Medical School and is board certified in internal medicine and cardiology. Prior to moving to Vanderbilt, he was clinical director at the center for translational medicine and a professor of Medicine at Temple University School of Medicine. He is a former president of Heart Failure Society of America.
Victoria Finamore, RN3, BSN, is a cardio-oncology nurse who has had experience in the care of cancer and cardiology patients. Victoria originally started out in the Vanderbilt Heart Institute as a volunteer where she helped patients check into their appointments by using an electronic kiosk. Following graduation with a Bachelor of Science in Nursing from East Tennessee State University, she completed a cardiac nurse residency at St. Thomas West Hospital. At St. Thomas, she worked as an inpatient cardiac critical care nurse. In 2018, Victoria joined Vanderbilt University Medical Center as a chemotherapy infusion nurse, where she championed many projects including Code Cart and Antineoplastic Occupational Safety. She also championed Virtual Reality for Oncology patients in order to improve their infusion experience. In 2019, she joined the Vanderbilt cardio-oncology program where she is expanding the role of nursing in the burgeoning field of cardio-oncology, promoting patient education, and is a Mock Code Leader.